Stephane Bancel, Chief Executive Officer at Moderna, Inc. (MRNA), sold 160,000 shares at $119.13 ($19.3M) on 2023-06-22, disclosed to the SEC on 2023-06-23.
Scheduled sale ($19.3M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $121.77 | 20,711 | $2.5M | 13.1% |
| 2 | $121.77 | 20,711 | $2.5M | 13.1% |
| 3 | $122.21 | 19,289 | $2.4M | 12.2% |
| 4 | $122.21 | 19,289 | $2.4M | 12.2% |
| 5 | $119.13 | 24,829 | $3.0M | 15.3% |
| 6 | $119.13 | 24,829 |
| $3.0M |
| 15.3% |
| 7 | $119.87 | 15,171 | $1.8M | 9.4% |
| 8 | $119.87 | 15,171 | $1.8M | 9.4% |
| Total | $120.70 avg | 160,000 | $19.3M | 100% |
| Filing → |
| MRNA | SELL | 2024-02-16 | $4.7M | — | Filing → |
| MRNA | SELL | 2023-06-30 | $6.6M | — | Filing → |
| MRNA | SELL | 2023-06-16 | $20.4M | — | Filing → |